Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor and targets it for degradation, has emerged as an important regulator of serum cholesterol levels and cardiovascular disease risk. Although much work is currently focused on developing therapies for inhibiting PCSK9, the endogenous regulation of PCSK9, particularly by insulin, remains unclear. The objective of these studies was to determine the effects of insulin on PCSK9 in vitro and in vivo. Approach and Results-Using rat hepatoma cells and primary rat hepatocytes, we found that insulin increased PCSK9 expression and increased low-density lipoprotein receptor degradation in a PCSK9-dependent manner. In parallel, hepatic Pcsk9 mRNA and plasma PCSK9 protein levels were reduced by 55% to 75% in mice with liver-specific knockout of the insulin receptor; 75% to 88% in mice made insulin-deficient with streptozotocin; and 65% in ob/ob mice treated with antisense oligonucleotides against the insulin receptor. However, antisense oligonucleotide-mediated knockdown of insulin receptor in lean, wild-type mice had little effect. In addition, we found that fasting was able to reduce PCSK9 expression by 80% even in mice that lack hepatic insulin signaling. Conclusions-Taken together, these data indicate that although insulin induces PCSK9 expression, it is not the sole or even dominant regulator of PCSK9 under all conditions.
L ow-density lipoprotein (LDL) receptors in the liver mediate clearance of >70% of LDL from the serum. 1 Consequently, the LDL receptor (LDLR) is a key determinant of serum cholesterol levels and cardiovascular disease risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of the LDLR. PCSK9 is a secreted protein which binds to the extracellular domain of the LDLR and targets it for degradation. 2, 3 Consequently, individuals with gain of function mutations in PCSK9 show increased levels of LDL cholesterol and increased risk of cardiovascular disease. 4 Conversely, individuals with loss of function mutations in PCSK9 manifest decreased levels of LDL cholesterol and reduced risk of cardiovascular disease. 5 Given the importance of PCSK9 in regulating the LDLR, a great deal of effort has recently been placed on producing inhibitors of PCSK9 for therapeutic use. Thus, antisense oligonucleotides and antibodies against PCSK9 have been developed, and preclinical studies have been promising. 6 However, much remains to be learned about the biology of PCSK9. In particular, identifying the endogenous regulators of PCSK9 is important because they could potentially be harnessed for therapeutic intervention. In addition, an understanding of the endogenous regulation of PCSK9 could guide the use of anti-PCSK9 therapies in different patient populations.
PCSK9 levels vary >100-fold between individuals. 7 Although some of this variability is because of genetic differences, and the use of cholesterol lowering drugs, it is also likely that changes in the hormonal milieu contribute. For example, thyroxine, estrogen, and glucagon have all been implicated in the regulation of PCSK9. 8 The effects of insulin, however, have been controversial. [9] [10] [11] To better understand the role of insulin in the regulation of PCSK9, we studied the effects of insulin in vitro and in vivo. We find that insulin, in hepatoma cells and primary rat hepatocytes, increases PCSK9 mRNA and protein, and decreases the half-life of the LDLR protein in a PCSK9-dependent manner. In parallel, the ablation of insulin signaling in the hepatocyte either by genetic knockout using albumin-Cre driven recombination of LoxP sites in the insulin receptor, destruction of the β-cells of the pancreas, or antisense oligonucleotide-mediated knockdown against the insulin receptor in ob/ob mice, decreases PCSK9.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
As expected, insulin increased mRNA levels of Ldlr in rat hepatoma cells. 12 It also induced the lipogenic enzyme fatty acid synthase (Fasn) and suppressed the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (Pck1; Figure 1A ). However, the effects on LDLR protein were more complex. Insulin treatment for 4 to 12 hours increased LDLR protein, in parallel with Ldlr mRNA. At 24 to 30 hours, however, insulin suppressed LDLR protein, and the amount of LDLR protein in cells treated with insulin for 24 hours fell below those observed in untreated cells ( Figure 1B ). In contrast, protein levels of fatty acid synthase, as well as transferrin receptor, were increased by insulin treatment at 24 to 30 hours ( Figure 1B ). Thus, insulin has a biphasic effect on LDLR protein, inducing it at early time points, and suppressing it at later time points.
The fact that insulin reduced LDLR protein but not Ldlr mRNA at later time points suggested that insulin might increase LDLR degradation. To test this, we measured the stability of LDLR protein by treating cells with cycloheximide, which blocks protein synthesis. LDLR protein levels fell more rapidly in the presence of insulin than in the absence of insulin ( Figure 1C ). Quantification of the immunoblots of 5 independent experiments revealed that insulin reduced the half-life of the LDLR by almost 33% ( Figure 1 . Biphasic regulation of low-density lipoprotein receptor (LDLR) by insulin. Rat hepatoma cells (A-C) or primary rat hepatocytes (D and E) were treated with insulin. Gene expression was measured by real-time polymerase chain reaction (A and D) and protein levels were determined by immunoblotting whole cell lysates (B, C, and E). A and B, Rat hepatoma cells were placed in serum-free medium 30 hours before harvest, and insulin was added for the indicated amount of time before harvest. C and E, Cells were treated with cycloheximide (CHX) for the indicated amount of time and insulin for a total of 12 hours before harvest. Primary rat hepatocytes were serum starved overnight and treated with insulin for 6 hours before harvest (D) or treated with CHX for the indicated amount of time and insulin for a total of 12 hours before harvest (E). In B, C, and E, representative gel images are shown on the left and protein quantifications on the right. Data represent mean and SEM of 3 to 5 independent experiments. In A and D, *P<0.05 compared with nonstimulated controls. In B, *, #, and & denote P<0.05 versus nonstimulated controls for LDLR, fatty acid synthase (FASN), and transferrin receptor (TFRC), respectively. In C and E, *P<0.05 for insulin treatment and #P<0.05 for CHX treatment. A.U. indicates arbitrary units; and PCK1, phosphoenolpyruvate carboxykinase.
showed that insulin increased the degradation of the LDLR ( Figure IC and ID in the online-only Data Supplement).
Primary rat hepatocytes are the most robust model system currently available for studying insulin action in vitro, particularly on lipid-related genes. 13, 14 In these cells, insulin increased mRNA levels of Ldlr by >2-fold and fatty acid synthase by 7-fold; in parallel, insulin suppressed Pck1 by 30-fold ( Figure 1D ). At the same time, insulin increased LDLR degradation: in the absence of insulin, 44% of LDLR protein remained after cycloheximide treatment, whereas in the presence of insulin, only 16% of LDLR protein remained after cycloheximide treatment ( Figure 1E ). PCSK9 2,3 and inducible degrader of the LDLR (IDOL) 15 promote the degradation of the LDLR. In rat hepatoma cells, Idol mRNA was not detectable in either the absence or presence of insulin (data not shown). However, insulin did induce Pcsk9 mRNA, cellular PCSK9, and secreted PCSK9 (Figure 2A ). To determine whether PCSK9 is necessary for the decrease in LDLR protein observed with prolonged insulin treatment, cells were treated with either a control adenovirus or an adenovirus encoding a shRNA against PCSK9, and then incubated in the presence or absence of insulin for 24 hours ( Figure 2B ). The shPCSK9 adenovirus effectively decreased PCSK9 protein in the cells and the media, both in the presence and absence of insulin ( Figure 2B ). In the absence of insulin, knockdown of PCSK9 increased LDLR as expected. Importantly, the ability of insulin to decrease LDLR protein was blunted by knockdown of PCSK9 ( Figure 2B ). Knockdown of PCSK9 did not, however, alter expression of fatty acid synthase or transferrin receptor ( Figure 2B ).
In primary rat hepatocytes, insulin produced an even more robust increase in PCSK9. Pcsk9 mRNA levels were increased 3-fold, and secreted PCSK9 protein was increased 3-fold ( Figure 2C A, Rat hepatoma cells were placed in serum-free medium 30 hours before harvest, and insulin was added for the indicated amount of time before harvest. B, Rat hepatoma cells were infected with adenovirus expressing a control shRNA (shControl) or an shRNA against PCSK9 (shPCSK9) and then treated with insulin for 24 hours. C and D, Primary rat hepatocytes were serum starved overnight and then stimulated with insulin for 6 hours (C) or 24 hours (D). D, PCSK9 protein in the medium was measured by immunoblotting; silver staining of the upper portion of the gel shows that similar amounts of protein were loaded. In A, B, and D, representative gel images and protein quantifications are shown. Data represent mean and SEM of 3 to 6 independent experiments. In A, *, #, and & denote P<0.05 versus nonstimulated controls for Pcsk9 mRNA levels, PCSK9 levels in cell, and medium, respectively. In B, *P<0.05 for the effects of insulin and #P<0.05 for the effects of Ad-shPCSK9. In C and D, *P<0.05 versus nonstimulated controls. A.U. indicates arbitrary units; FASN, fatty acid synthase; and TRFC, transferrin receptor.
of a PCSK9 promoter luciferase construct by 2-fold ( Figure  IIB in the online-only Data Supplement) and the ability of insulin to induce Pcsk9 mRNA in primary rat hepatocytes was entirely abolished by treatment with actinomycin D, which interferes with transcription ( Figure IIA in the online-only Data Supplement). Moreover, insulin induction of the PCSK9 promoter was blocked by inhibition of the phosphoinositide 3-kinase signaling pathway, which mediates many of insulin's metabolic effects ( Figure IIC in the online-only Data Supplement); it was also blocked by mutation of the sterol response element and hepatocyte nuclear factor 1 (HNF1) binding sites, but not the Sp1 site ( Figure IID in the onlineonly Data Supplement). We therefore examined expression of sterol regulatory element binding protein-1a (Srebp-1a), Srebp-2, and Srebp-1c, as well as HNF-1α and HNF-1β, in response to insulin. In rat hepatoma cells, only Srebp-2 was increased at the mRNA level ( Figure IIE in the online-only Data Supplement). In primary rat hepatocytes, Srebp-1c was increased 12-fold and Srebp-1a was increased 2-fold, whereas Srebp-2 and the HNFs were not changed ( Figure IIF in the online-only Data Supplement). Collectively, these data support the notion that insulin induces Pcsk9 transcription via the SREBPs, but do not rule out a role for other factors.
To determine the effects of insulin on PCSK9 in vivo, we used liver insulin receptor knockout (LIRKO) mice and their controls. LIRKO hepatocytes lack insulin receptors making them incapable of insulin signaling. 16 Consequently, LIRKO mice are hyperglycemic and hyperinsulinemic. 16 We have previously shown that LIRKO mice show decreased levels of SREBP-1, SREBP-2, and the SREBP target genes. 17, 18 Moreover, on an atherogenic Paigen diet (15% dairy fat, 1% cholesterol, 0.5% cholic acid), 19 LDLR protein levels are markedly decreased. 17 We therefore measured PCSK9 and LDLR in LIRKO and control mice fed either a chow or atherogenic Paigen diet for 4 weeks (Figure 3 ). On the chow diet, LIRKO mice showed decreased levels of plasma PCSK9, decreased Pcsk9, and Ldlr mRNA levels, and normal LDLR protein levels ( Figure 3A -3C and 3E). These data suggest that insulin increases both LDLR synthesis and degradation, and is consistent with our in vitro data showing increased Pcsk9 and Ldlr mRNA in the presence of insulin.
The Paigen diet reduced Pcsk9 and Ldlr mRNA in both control and LIRKO mice. However, control mice maintained normal levels of LDLR protein on the Paigen diet ( Figure 3E ). LIRKO mice, however, showed a marked reduction in LDLR protein and developed severe hypercholesterolemia on the Paigen diet ( Figure 3E and 3F ). Why LDLR protein was decreased in the Paigen-fed LIRKO mice is still under investigation, but may be because of decreased Ldlr mRNA and increased Idol expression ( Figure 3C and 3D ).
Pcsk9 has also been previously shown to be decreased by fasting. 9, 20 To determine whether the effects of fasting on Pcsk9 were mediated by insulin, we subjected control and LIRKO mice to a 24-hour fast. Interestingly, fasting reduced Pcsk9 mRNA by 95% in control mice, and 80% to 90% in LIRKO mice ( Figure 4A) . Similar effects were observed on Ldlr mRNA, but the effects were more modest ( Figure 4A ). Conversely, refeeding (ie, feeding mice a high carbohydrate diet after a 24-hour fast) increased Pcsk9 mRNA by almost 60-fold in control mice, but only 30-fold in LIRKO mice ( Figure 4B ). In parallel, refeeding induced Ldlr 4-fold in control mice, but only 2-fold in LIRKO mice ( Figure 4B ). Idol mRNA, however, was again slightly higher in LIRKO mice, but unchanged by fasting or refeeding ( Figure 4A and LIRKO mice in the fasted state (0 hours of refeeding) and after 24 hours of refeeding, just as it was in chow-fed mice ( Figure 4C ). However, after 6 or 12 hours of refeeding, LIRKO mice showed lower levels of LDLR protein than controls, despite the fact that Pcsk9 levels were lower. The fact that Pcsk9 is still regulated by fasting in LIRKO mice indicates that other factors besides hepatic insulin action are important in the regulation of Pcsk9. One such factor could potentially be glucagon, which has previously been shown to suppress hepatic Pcsk9 mRNA in vivo in rats. 8 Indeed, glucagon suppressed PCSK9 mRNA and protein levels by 50% in primary rat hepatocytes ( Figure IIIA and IIIC in the online-only Data Supplement). Glucagon also suppressed mRNA levels of Srebp-1c and Srebp-2 by 20% to 50%, whereas it increased expression of Pck1 9-fold ( Figure IIIA and IIIB in the onlineonly Data Supplement). More importantly, although glucagon decreased Ldlr mRNA by 20%, it increased LDLR protein by 2-fold ( Figure IIIA and IIID in the online-only Data Supplement).
We also examined the effects of insulin in the context of insulin deficiency and selective insulin resistance. Selective insulin resistance is a key feature of type 2 diabetes mellitus, in which not all signaling pathways seem to become resistant to insulin-some seem to remain sensitive to insulin and are driven to excess by the hyperinsulinemia which coevolves with insulin resistance. 14 As a model of insulin deficiency, we chose streptozotocin-treated mice, as streptozotocin destroys the β-cells of the pancreas. As a model of selective insulin resistance, we chose leptin-deficient, obese ob/ob mice. To compare directly the effects of insulin deficiency and selective insulin resistance, we studied in parallel lean, wild-type mice treated with vehicle (WT); lean, wild-type mice treated with streptozotocin (STZ); and ob/ob mice treated with vehicle (ob/ob). Prior studies have reported both STZ and ob/ ob mice to be hyperglycemic and hyperglucagonemic, although STZ mice are hypoinsulinemic and lean or underweight and ob/ ob mice are hyperinsulinemic and obese 21 (see also Table II in the online-only Data Supplement).
Liver gene expression analysis by real-time polymerase chain reaction revealed that Pcsk9 was markedly decreased in streptozotocin-treated mice but not ob/ob mice (Table) . In parallel, the SREBP transcription factors which drive Pcsk9, Srebp-1c, 9 and Srebp-2, 22 and their other targets, fatty acid synthase, stearoyl-CoA desaturase 1 (Scd1), 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), and farnesyl diphosphate synthase (Fdps), were decreased by 44% to 98% in streptozotocin-treated mice. In ob/ob mice, however, these genes were generally unchanged, or in the case of Srebp-1c, Fasn, and Scd1, increased, consistent with prior studies. 11, 23 The changes in fatty acid synthase and stearoyl-CoA desaturase 1 were also evident at the protein level because they were markedly induced in ob/ob livers ( Figure 5A) . In contrast, both streptozotocin-treated mice and ob/ob mice showed increased expression of the gluconeogenic genes, glucose-6-phosphatase (G6pc), Pck1, and peroxisome proliferator-activated receptor gamma coactivator 1α (Ppargc1α) ( Table) , and were hyperglycemic ( Table II in the online-only Data Supplement). Idol mRNA was slightly elevated in ob/ob livers (Table) . Plasma PCSK9 levels mirrored liver Pcsk9 mRNA levels ( Figure 5B) , with STZ mice showing a 70% reduction in plasma PCSK9 levels. However, both STZ and ob/ob mice showed increased LDL cholesterol, despite a tendency toward elevated LDLR protein ( Figure 5A and 5C ), likely because of increased secretion of very-low density lipoprotein (VLDL), the precursor of LDL. 24 To directly test the role of insulin signaling in the regulation of PCSK9 in ob/ob mice, we knocked down the insulin receptor using antisense oligonucleotides (ASO). Thus, ob/ob mice and their wild-type controls were injected weekly for 4 weeks with either a control ASO or an ASO against the insulin receptor. Such treatment would abolish the ability of insulin to act on the hepatocyte.
We have previously shown that antisense-mediated knockdown of the insulin receptor worsens hyperglycemia, but decreases levels of Srebp-1c, its lipogenic targets, and hepatic steatosis in ob/ob mice. 25 Consistent with this, treatment with ASO against the insulin receptor markedly decreased insulin receptor protein levels in the livers of both wild-type and ob/ob mice ( Figure 5D ). Similarly, fatty acid synthase protein, which was increased in the livers of ob/ob mice, was decreased by knockdown of the insulin receptor in mice of both genotypes ( Figure 5D ).
Knockdown of the insulin receptor decreased both Pcsk9 mRNA ( Figure 5E ) and plasma PCSK9 in ob/ob mice ( Figure 5F ), indicating that insulin promotes the expression of Pcsk9 in ob/ ob mice. However, knockdown of the insulin receptor did not significantly alter Pcsk9 in lean mice. Knockdown of the insulin receptor also decreased Ldlr and Idol mRNA levels in ob/ob but not lean mice ( Figure 5G and 5H) ; nonetheless, LDLR protein levels were not markedly different between groups ( Figure 5D ).
Discussion
PCSK9 has emerged as an important regulator of the LDLR and a novel therapeutic target. Here, we show that insulin promotes the degradation of the LDLR in vitro in a PCSK9dependent manner. However, in vivo, decreased levels of PCSK9 in insulin-deficient states are generally not associated with an increase in LDLR protein; indeed, in LIRKO mice refed a carbohydrate diet for 6 to 12 hours, or LIRKO mice fed a Paigen diet, LDLR protein is decreased. These data point to the fact that insulin regulation of LDLR is complex, and suggest that in vivo, insulin may act through PCSK9-independent mechanisms to increase LDLR protein expression.
Our data in vivo support the notion that insulin can directly induce PCSK9 expression. Thus, LIRKO mice, ob/ob mice treated with ASO against the insulin receptor, mice treated with streptozotocin, and fasted mice all show decreased levels of Pcsk9. However, our data also point to the fact that insulin is not always a major regulator of PCSK9 in vivo. First, LIRKO mice, despite their inability to respond to insulin, still show an 80% reduction of PCSK9 on fasting. Consequently, in the fasted state, the effects of insulin receptor knockout on Pcsk9 expression are abolished. Second, in ob/ob mice, insulin clearly promotes the expression of PCSK9, as knockdown of the insulin receptor in these mice decreases PCSK9 expression. However, given that ob/ob mice are markedly hyperinsulinemic relative to their lean controls, it might be expected that PCSK9 levels would be supranormal. That they are not suggests that the effects of hyperinsulinemia are balanced by some other factor in the diabetic state which suppresses PCSK9. Finally, and perhaps most importantly, the acute knockdown of the insulin receptor in lean, wild-type mice by ASO does not significantly decrease PCSK9 levels. Similarly, adenoviral-mediated delivery of Cre recombinase into mice carrying a floxed allele of the insulin receptor did not consistently decrease PCSK9 expression (data not shown). Why knockdown of the insulin receptor in wildtype mice has little effect on Pcsk9, whereas LIRKO mice show markedly reduced Pcsk9 is not clear. However, LIRKO mice have chronic insulin resistance, starting in the perinatal period, which leads to peripheral insulin resistance. 26 This peripheral insulin resistance may be necessary to unmask the effects of hepatic insulin signaling on the liver, perhaps by altering glucagon signaling or whole body cholesterol homeostasis.
Our data showing that insulin promotes PCSK9 expression is also consistent with prior reports showing decreased Pcsk9 by fasting 9, 20 and increased Pcsk9 in mice subjected to a hyperinsulinemic euglycemic clamp. 9, 11 However, studies by Ai et al 10 reported a 2-fold increase in Pcsk9 mRNA on knockdown of the insulin receptor in mice using an adenovirus encoding a shRNA. One important difference in the experimental design of this study is that Ai et al studied mice that had been fasted for 5 hours before euthanize. As shown in Figure 4B , a 24-hour fast abolishes the effects of insulin receptor knockout on Pcsk9. Indeed, even a fast of only 5 hours is sufficient to reduce Pcsk9 levels by 60% in wild-type mice ( Figure IV in the online-only Data Supplement). This is not surprising given the facts that nuclear levels of SREBP-1 and SREBP-2 are markedly decreased by 6 hours of fasting 27 and that mice lacking both SREBP-1 and SREBP-2, because of knockout of SREBP cleavage-activating protein (Scap), show markedly reduced Pcsk9 levels. 28 Thus, it is likely that in the studies by Ai et al, fasting abrogated the effects of insulin, unmasking the effects of other factors on Pcsk9.
One such factor could be glucagon. Despite its hyperglycemic effects, glucagon has beneficial effects on the LDLR. Interestingly, it was shown 20 years ago that glucagon increases LDLR protein, but not mRNA levels in rats. 29 Our data show that glucagon suppresses Pcsk9 expression in hepatocytes ( Figure IIIA and IIIC in the online-only Data Supplement). Thus, fasting suppresses PCSK9 in 2 ways: it lowers insulin and raises glucagon. The increase in glucagon could account for the ability of fasting to decrease Pcsk9 mRNA even in the livers of LIRKO mice, which are unable to respond to insulin. Similarly, increased glucagon levels in ob/ob mice 30 could potentially mitigate the effects of hyperinsulinemia on Pcsk9 in the liver.
Studies in humans show that PCSK9 levels are normal or increased in obesity/type 2 diabetes Mellitus. 7, 31 As diabetic patients are at high risk for cardiovascular disease, they are important candidates for PCSK9 therapy. Our data indicate that although insulin promotes the expression of PCSK9, other factors may play a dominant role. Defining these other factors and understanding how they interact with insulin in the control of PCSK9, the LDLR and cardiovascular disease risk will be important to developing better treatments for diabetic patients. Figure 5 . Proprotein convertase subtilisin/kexin type 9 (PCSK9) expression is decreased in mice with insulin deficiency, but not selective insulin resistance. Eight-to 12-week-old male mice were euthanized in the nonfasted state (n=4-5 mice per group). A-C, Vehicle-treated ob/ob mice (ob/ ob) and lean, wild-type controls treated with either vehicle (WT) or streptozotocin (STZ) were studied in parallel. Protein levels were measured by immunoblotting (A), plasma PCSK9 levels were measured by ELISA (B), and low-density lipoprotein (LDL) cholesterol levels were measured by colorimetric assays (C). *P<0.05 compared with lean mice treated with vehicle and &P<0.05 compared with STZ-treated group. D-H, ob/ob mice (ob/ ob) and their lean, wild-type controls (WT) were treated with control antisense oligonucleotides (ASO) or ASO against the insulin receptor (INSR) for 4 weeks. Protein levels were measured by immunoblotting liver extracts (D), hepatic gene expression was measured by real-time polymerase chain reaction (E, G, and H), and plasma PCSK9 levels were measured by ELISA (F). *P<0.05 compared with control ASO-treated mice and #P<0.05 compared with WT treated with the same ASO. In A and D, representative gel images (left) and protein quantifications (right) are shown. Data present the mean and SEM; control mice treated with vehicle or control mice treated with control ASO were set to 1. A.U. indicates arbitrary units; FASN, fatty acid synthase; IDOL, inducible degrader of the LDLR; LDLR, low-density lipoprotein receptor; and SCD1, stearoyl-CoA desaturase 1.
Proprotein convertase subtilisin/kexin type 9 is a promising therapeutic target. Here, we show that insulin induces proprotein convertase subtilisin/kexin type 9, although other hormones and factors are clearly involved. Dissecting the endogenous regulators of proprotein convertase subtilisin/kexin type 9 is an important step toward the rational utilization of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and obesity.
Significance

